Gilead Gives Up On Galapagos's Filgotinib In RA
Belgian Biotech's Stock Battered
A disappointing meeting with the FDA means "we no longer see a viable path to US approval in this indication,” said Gilead CEO Daniel O'Day, as Galapagos assumes sole responsibility for the commercialization of the JAK inhibitor in Europe.
